Here are the DEF 14A proxy statements from Intellia Therapeutics, Inc (NTLA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow NTLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTLA filings page.
Intellia Therapeutics, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 9, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of April 10, 2026 may vote on three main items: electing three class I directors, ratifying Deloitte & Touche LLP as independent auditor for 2026, and approving on a non-binding advisory basis the compensation of named executive officers. The board unanimously recommends voting in favor of all three proposals. The proxy statement also explains virtual attendance and voting procedures, quorum and vote standards, board composition, governance practices, and committee structures, including audit, compensation, nominating and science and technology committees.